{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-019455","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.785475+00:00","generated_at":"2026-06-14T11:30:20.800511+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"INVO Bioscience receives Nasdaq delisting notice for failure to meet $2.5M equity minimum","bullets":["Nasdaq notified INVO on May 23, 2023, of non-compliance with Listing Rule 5550(b)(1) requiring $2.5M stockholders' equity.","Company failed to regain compliance by the May 22, 2023 extension deadline.","INVO plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.","No assurance that the Panel will grant continued listing or an extension.","Stockholders' equity deficiency triggers potential delisting from Nasdaq Global Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-019455","json":"https://secwatch.observer/filing/0001493152-23-019455.json","markdown":"https://secwatch.observer/filing/0001493152-23-019455.md","text":"https://secwatch.observer/filing/0001493152-23-019455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223019455/0001493152-23-019455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223019455/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:30:20.800511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f8a61429682146e48cc2dad81d058185a55c27d","claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 23, 2023, INVO Bioscience, Inc. (the “Company”) was notified by the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Rule”), as of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing be","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223019455/0001493152-23-019455-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}